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Abstract
Type 1 diabetes is increasing in incidence in many parts of the world and it might be imagined that the pathological
processes that underlie disease progression are firmly understood. However, this is not the case; rather, our collective
understanding is still surprisingly rudimentary. There are various reasons for this but one of the most important is that
the target organ (the pancreas) has been examined at, or soon after, diagnosis in only a small number of cases
worldwide over the past half a century. This review provides a summary of some of the insights gained from these
studies and highlights areas of ongoing uncertainty. In particular, it considers the process of insulitis (a form of islet
inflammation that occurs characteristically in type 1 diabetes) and discusses the factors that may influence the access of
immune cells to the beta cells. Attention is also drawn to recent evidence implying that two distinct profiles of insulitis
exist, which occur differentially in people who develop type 1 diabetes at increasing ages. Emphasis is also placed on
the emerging (and somewhat surprising) consensus that the extent of beta cell loss is variable among people with type 1
diabetes and that many (especially those who are older at onset) retain significant numbers of insulin-producing cells
long after diagnosis. We conclude by emphasising the importance of renewed efforts to study the human pancreas at
disease onset and consider how the current insights may inform the design of future strategies to slow or halt the rate of
beta cell loss.
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Historical perspectives
The concept that type 1 diabetes represents a specific disease
with a unique aetiology only gained acceptance in the mid-
1970s [1] although earlier pioneering studies (mainly byWilly
Gepts in the 1960s [2]) had hinted at this conclusion by re-
vealing some of the characteristic pancreatic pathology now
known to define it. Progress has remained sluggish, however;
largely because a meticulous examination of the target organ is
not easily achieved in living individuals. Efforts are underway
to improve non-invasive imaging [3] but, in humans, the pan-
creas remains largely inaccessible and surgical interventions
still carry a serious risk. Useful rodent models have been de-
veloped to assist in defining the aetiology of type 1 diabetes
[4–6] but there are fundamental differences between the rodent
and human pancreas with respect to islet architecture [7], in-
nervation [8, 9] and vasculature [8–10], which require caution
to be exercised.
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Looking back over the last 50 years, it is sobering to realise
that fewer than 600 human pancreatic samples in total have
been studied from people with type 1 diabetes or are available
in pancreatic biobanks (Fig. 1; Table 1). Moreover, only a
small subset of these come from young people with recent-
onset disease. The largest collections are held in the Exeter
Archival Diabetes Biobank (EADB) and the Network for
Pancreatic Organ Donors with Diabetes (nPOD) [11]. The
EADB is an archival collection comprised of predominantly
post-mortem pancreas samples collected from young people
(<20 years old) with recent-onset (<2 years) disease who died
between 1935 and the mid-1990s [12]. Importantly, it contains
the world’s largest collection of pancreas tissue from individ-
uals diagnosed with diabetes under the age of 10 years (a
comparison of the two largest collections is shown in Fig. 2;
Table 2). However, most specimens were obtained post-
mortem and the tissue is of variable quality such that its suit-
ability for certain applications (e.g. RNA sequencing) is limit-
ed. By contrast, nPOD tissues are harvested and processed
according to optimised standard operating procedures and
samples are available for multiple applications [11, 13, 14].
Nevertheless, most nPOD pancreases come from older-onset
donors with longer disease duration (Fig. 2; Table 2) and only a
single organ is currently available from a donor under the age
of 7 years with a short duration (<2 years) of disease. Newer
initiatives, including the European INNODIA consortium and
a Medical Research Council (MRC)-funded pancreas collec-
tion (the Quality in Organ Donation [QUOD] Biobank; coor-
dinated from the University of Newcastle, UK) promise to
deliver high-quality samples in the future. Further study of
pancreas biobanks remains paramount for an improved under-
standing of diabetes [15].
Islet structure and composition
In humans, islets are widely dispersed across the pancreas,
although they may be present at higher density in the head
and body of the organ than in the tail [16]. Each islet has a
multicellular structure and, in rodent species, the beta cells are
localised at the centre with the remaining endocrine cell types
arranged in a peripheral ‘mantle’. In human islets, the beta and
non-beta endocrine cells occur in a less structured conforma-
tion, particularly in larger islets [7, 16] (Fig. 3). Moreover, the
proportions of the various endocrine cells are different be-
tween species, with a smaller overall percentage of beta cells
(50–60%) in humans than in rodents [16, 17].
Insulitis
An important advance arising from studies of the human pan-
creas in type 1 diabetes has been the description of insulitis, a
process of immune cell infiltration into islets [18] (Fig. 4).
This is also seen in animal models but insulitis is found at a
lower frequency across the islet population in humans than in
rodents, and the proportion of the various individual immune-
cell subtypes differ between species (e.g. CD8+ T cells dom-
inate human insulitis, whereas CD4+ cells are predominant in
NOD mice). One note of caution, however, is that some evi-
dence implies that the period spent in intensive care prior to
organ recovery can influence the extent of immune-cell infil-
tration into the human pancreas [18].
Insulitis occurs mainly within the residual insulin-
containing islets of people with recent-onset type 1 diabetes
and many fewer insulin-deficient islets are inflamed [12,
19–21]. This implies that immune cells are recruited and
retained primarily in response to factors emanating from their
target beta cells, although the proportion of islets with inflam-
mation varies, not simply in response to beta cell numbers, but
also according to the age at disease onset. For example, among
individuals diagnosed aged 13 years or older, the proportion
of residual insulin-containing islets with insulitis is around
25%, whereas it is much higher (~80%) in those diagnosed
in the very early years of life (<7 years of age) [22]. These
statistics suggest that young children may have a more aggres-
sive form of the disease. A further implication is that, among
older individuals, functional insulin deficiency can occur de-
spite the retention of a significant reserve of the hormone. This
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Fig. 1 Cumulative number of type 1 diabetes cases that have become
available for study over the past 50 years. Fewer than 600 human pan-
creatic samples are available for study of the aetiopathology of type 1
diabetes in the various collections held across the world. Some form part
of larger collections while other samples are cited only in specific publi-
cations (defined as ‘Publication’ in the key). These have been accumu-
lated over time and the collection of samples is ongoing in the nPOD,
European nPOD (EUnPOD), Nordic Network for Clinical Islet
Transplantation and QUODBiobank initiatives. Despite this, only a small
subset of samples come from individuals with recent-onset (≤2 years)
disease. DiViD, Diabetes Virus Detection Study. This figure is available
as part of a downloadable slideset
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points not only to beta cell loss as a cause of type 1 diabetes,
but also suggests an insulin-secretory dysfunction among the
residual, non-inflamed islets in some individuals. These con-
clusions are supported by in vitro studies showing that the
immediate post-isolation deficit in glucose-induced insulin
secretion in the islets of people with type 1 diabetes may
improve with time in culture [23].
The occurrence of insulitis is not restricted solely to the
period immediately after disease onset but it can also be
found in the insulin-containing islets of individuals with
long-duration disease [21]. By contrast, it is less clear how
long before diagnosis insulitis occurs in people who are
progressing to disease. This is much more difficult to eval-
uate, of course, because prediction of disease onset is still an
imperfect art. Nevertheless, it has proved so hard to uncover
firm evidence of insulitis in individuals prior to disease on-
set that In’t Veld has defined the process as an ‘elusive
lesion’ [21, 24–26].
Progression of insulitis The relative difficulty in identifying
insulitis in the human pancreas has led to the publication of
an international consensus statement by which insulitis can be
defined [27]. This represents a welcome advance since vary-
ing definitions have appeared in the literature over time [11,
19, 25, 28–31]. The consensus definition notes that ‘the lesion
should be established in a minimum of three islets, with a
threshold level of ≥15 CD45+ cells/islet before the diagnosis
can be made’ [27, 32]. The utility of this statement has been
challenged [33], but it remains an internationally accepted
working definition [32].
Although the precise composition of the immune infiltrate
is variable between islets and among individuals, important
categories of insulitis have now been defined. In particular, in
humans, CD8+ T cells are predominant, whereas CD4+ cells
are often represented only as a minority population [19, 21,
34, 35]. In addition, the proportion of CD20+ cells (B cells) is
Table 1 Principal type 1 diabetes pancreas biobanks available for study
Biobank name; location Number of donors
with type 1 diabetes
Examples of other donor
types within the collection
Website link
EADB; UK 169 No diabetes
AAb+ without diabetes,
Type 2 diabetes
Cystic fibrosis
Coxsackie-infected neonates
http://foulis.vub.ac.be/ (accessed 28 August 2018)
nPOD; USA 135 No diabetes
AAb+ without diabetes
Type 2 diabetes
Cystic fibrosis related diabetes
Pancreatitis
Gestational diabetes
Pancreatic transplant
www.jdrfnpod.org/ (accessed 28 August 2018)
European nPOD (EUnPOD); Italy 11 No diabetes NA
Belgium Diabetes Registry, (includes
the Willy Gepts Collection);
Belgium
73 (datasets for n = 22
available online)
No diabetes
AAb+ without diabetes
www.diabetesbiobank.org/ (accessed 28 August
2018)
http://gepts.vub.ac.be/ (accessed 28 August 2018)
Nordic Network for Clinical Islet
Transplantation; Sweden
15 No diabetes
AAb+ without diabetes
Type 2 diabetes
http://nordicislets.medscinet.com (accessed 28
August 2018)
MRC QUOD Biobank; UK 1 No diabetes http://gtr.ukri.org/projects?ref=MR%2FR014132%
2F1 (accessed 28 August 2018)
Autoantibody positive, AAb+; NA, not available
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Fig. 2 Comparison of pancreas samples available from donors with re-
cent-onset (≤2 years) type 1 diabetes in the two largest collections avail-
able for study. Most of the pancreas samples available within the EADB
(blue circles) come from individuals who were under the age of 20 years
at diagnosis. Many had been diagnosed with type 1 diabetes for less than
6 months at the time of recovery of the gland. By contrast, those in the
nPOD collection (red squares) were mainly older at onset. This figure is
available as part of a downloadable slideset
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variable [34–36] since, in very young children (≤7 years of
age) these are present in relative abundance in inflamed islets,
whereas their proportion is much lower in those who are older
at diagnosis [34, 35]. The consequences of this difference (and
the factors that underlie it) remain uncertain, but such variabil-
ity must be considered when designing immunotherapeutic
trials intended to reduce the rate of beta cell demise. In addi-
tion to lymphocytes, other immune-cell subtypes, including
neutrophils [37], mast cells [38] and natural killer cells [39],
have been reported to infiltrate the pancreas in, at least, some
individuals with type 1 diabetes.
Work in the NOD mouse suggests the existence of sequen-
tial ‘stages’ of insulitis [40]; among these is a feature known as
‘peri-insulitis’ in which islets are surrounded by immune cells
but not infiltrated by them. This is followed by more complete
infiltration, where islets are invaded and the killing of beta
cells occurs at high frequency. Equivalent stages are not seen
in humans and invasive insulitis is detected only rarely. This
suggests either that, in humans, the killing of beta cells is
mediated by the very small number of immune (presumably
CD8+) cells that penetrate into the endocrine cell milieu or,
alternatively, that killing does not require direct contact be-
tween immune and beta cells. A third possibility also exists,
in which the immune cells play (at best) only a minor role in
beta cell death. In this context, recent evidence implies that
many of the CD8+ cells present in insulitic lesions are resident
memory cells, which lack a proinflammatory gene expression
signature [41]. Nevertheless, it is also clear that some of the
influent CD8+ T cells are reactive against islet antigens, sug-
gesting an aggressive intent [42–44].
The histological feature referred to above termed ‘peri-
insulitis’ mirrors most closely the arrangement of immune
cells found in many inflamed islets in human type 1 diabetes.
However, unlike the situation in NOD mice, where islets are
surrounded by successive banks of lymphocytes, the influent
immune cells are fewer in number in human islets and tend to
adorn one of the poles [27, 45] (Fig. 4). This distribution
suggests that immune cells are initially attracted to the islet
environment but, on arrival, they encounter a barrier to entry.
This is probably the ‘peri-islet membrane’, a structure that
may require considerable re-modelling in order to permit im-
mune cell entry.
Islet extracellular matrix
The peri-islet membrane forms part of a complex extracellular
matrix that serves both to contain the islet cells and to restrict
the access of influent immune cells (reviewed in [46]). The
structure is sufficiently loose that soluble molecules, including
islet hormones, chemokines and cytokines, can penetrate, but
it is more restrictive to the passage of cells. It takes the form of
a basement membrane consisting of a matrix of collagen
(mainly type IV) and a multitude of associated (glyco)pro-
teins, including perlecan and various laminins. The composi-
tion of this membrane is very similar in mouse and human
islets, although there are important differences in laminin
composition [46, 47]. Beneath the basement membrane is an
interstitial matrix made up of other collagen isoforms (mostly
types I, III and VI) plus fibronectin and large glycoproteins
belonging to the fibrillin and matrilin families. Together these
represent a formidable barrier to immune cells.
Table 2 Comparison of the type 1 diabetes samples available within the
EADB and the nPOD pancreas collection
Variable EADB nPOD
Age at onset (years) 11.00 (5.0–16.0) 11.52 (6.2–18.4)
Age at onset (years), range 0.5–40 1–82
Disease duration (years) 0.143 (0.04–3.75) 12.00 (5.5–23.0)
Disease duration (years), range 0–19 0–84
Donors with ≤1 year duration
n 85 11
Age of onset (years) 12.0 (6.0–17.0) 17.4 (11.6–23.0)
Donors ≤7 years old at onset
n 49 48
Duration (years) 0.25 (0.0–6.0) 23.0 (10.5–34.0)
Donors ≤20 years old at onset
n 116 107
Duration (years) 0.17 (0.0–4.0) 14.0 (7.0–24.5)
Data presented as median (interquartile range) unless otherwise stated.
Onset and duration data are available for 128 EADB cases and 133 nPOD
cases
Fig. 3 Cellular composition of a human islet of Langerhans from a
healthy individual. Individual endocrine cell subtypes were identified
by immunofluorescent analysis after staining with antisera directed
against insulin (light blue), glucagon (red) and somatostatin (green).
Cell nuclei were stained with DAPI (dark blue). Scale bar, 25 μm. The
image was captured in our laboratory in Exeter and is from a case held in
the EADB collection. This figure is available as part of a downloadable
slideset
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In order to gain entry to the islet milieu, the basement
membrane components must be degraded and, in humans, this
occurs in a targeted manner close to the point of immune
attack, rather than as a more generalised disintegration of the
basement membrane around the whole islet [47]. Interestingly,
recent modelling of the process using mathematical simula-
tions has suggested that permeation of the islet basement
membrane may be the rate-limiting step in beta cell death in
type 1 diabetes [48].
Korpos and colleagues have attempted to define the origin
and identity of the enzymes responsible for mediating the
breakdown of the islet basement membrane during insulitis
and, based on both inhibitor and mRNA expression studies
using laser capture microdissected islets, they have proposed
that cathepsins are prime candidates [47]. High-resolution
analysis has led to the conclusion that macrophages and den-
dritic cells are the likely source of these enzymes and such
cells are present in modest numbers during the autoimmune
attack. Whether the accompanying lymphocytes play a direct
role by also secreting additional proteases, remains to be
established.
Islet chemokine expression
A key question that arises when considering the mechanisms
by which immune cells might reach the islet, is the nature of
the chemoattractant. It has been widely assumed that islets are
induced to secrete chemokines during the initiation phase of
beta cell destruction and that relevant immune cells then mi-
grate to the source of these molecules. In support of this,
several chemokines have been detected in inflamed islets,
including, most frequently (but not exclusively [49]), the (C-
X-C motif) ligand (CXCL)10 [50, 51]. This interacts with its
cognate receptor, CXCR3, which has been detected on a sub-
set of CD3+ cells present in immune infiltrates, including on a
proinsulin-directed, autoreactive clone isolated from an indi-
vidual with type 1 diabetes [50]. It is also known that beta cells
can directly produce certain cytokines, including IL-1β [52],
which might play a role in mediating their demise.
Islet HLA class I hyperexpression
A characteristic feature seen in the majority of insulin-
containing islets in individuals with type 1 diabetes is
hyperexpression of HLA class I [53, 54]. This was first de-
scribed in early studies by Bottazzo’s group [55] and Foulis
et al [53], but has subsequently been confirmed by others [54,
56]. Importantly, HLA class I hyperexpression is not solely
restricted to the beta cells in inflamed islets since it occurs in
all islet endocrine cells [54], suggesting that the cells are
responding to a locally produced agent that is present uniquely
in type 1 diabetes. The response is also independent of the
simultaneous presence of infiltrating immune cells since it
occurs in islets that are inflamed and those that are not [53].
Importantly, hyperexpression of HLA class I does not persist
in islets that are deficient in beta cells [45, 53, 54].
Foulis and colleagues were able to correlate HLA class I
hyperexpression with the presence of IFN-α in islets studied
in situ [57] and subsequent in vitro experiments have con-
firmed that exposure of isolated human islets to IFN-α causes
HLA class I hyperexpression [58, 59]. Set against this, gene
expression studies performed on laser captured, microdissect-
ed islets from pancreas biopsies recovered from living indi-
viduals soon after the diagnosis of type 1 diabetes have sug-
gested that IFN-α levels are not elevated in these samples
[51]. Thus, a dilemma remains.
Beta cell loss in type 1 diabetes
By convention, it has been tacitly assumed that the demise of
beta cells consequent to insulitis is mediated by enhanced
apoptosis since exposure of human islets (or clonal beta cells)
to proinflammatory cytokines, in vitro, leads to apoptosis [60].
Despite this, only modest increases in beta cell apoptosis have
been detected in human type 1 diabetes [28] and this may
reflect the rapid clearance of apoptotic cells by resident mac-
rophages, which are known to patrol the islet milieu [19].
However, this explanation may also obscure a more funda-
mental possibility that beta cell apoptosis occurs much less
frequently than is supposed. This concept is gaining accep-
tance in type 2 diabetes, in which beta cell depletion is increas-
ingly attributed to a process of either de- or trans-
Fig. 4 Example of an inflamed islet from a child newly diagnosed with
type 1 diabetes. Lymphocytes were immunostained in brown with an anti-
body directed against CD45. Small numbers of lymphocytes are found
within the core of the islet but most are located peripherally, with the
majority focused at one pole of the islet. Scale bar, 20 μm. The image
was captured in our laboratory in Exeter and is from a case held in the
EADB collection. This figure is available as part of a downloadable slideset
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differentiation, whereby the beta cell phenotype is lost but the
cells themselves remain [61]. Levine’s group have provided
evidence for the emergence of larger-than-expected numbers
of delta cells in human islets during long term type 1 diabetes
and have proposed that these may arise by a process of beta
cell trans-differentiation [62]. This idea requires further veri-
fication but implies that beta cells may not always die in large
numbers, after all.
A further feature revealed in recent studies of whole pan-
creas organs recovered from donors with type 1 diabetes is
that the depletion of the islet cells correlates with a more
generalised deficit in total pancreatic mass [63]. This was first
mooted in the study by Foulis and Stewart [20] and more
recent examination of transplant-grade samples from within
the nPOD collection has revealed an ~40% reduction in rela-
tive pancreas weight in type 1 diabetes vs age matched con-
trols [64]. Thus, the traditional view that the pathological ef-
fects associated with type 1 diabetes are restricted solely to the
endocrine compartment of the tissue may require revision and
increasing evidence suggests that imbalances in immune-cell
infiltration also extend more widely across the gland [37, 64].
Conclusion
Our understanding of the aetiopathology of type 1 diabetes has
advanced greatly since the pioneering studies by Gepts [2],
mainly thanks to the opportunity to study additional rare and
precious pancreas samples recovered from individuals with the
disease. Nevertheless, the task is not complete and the more we
look, the more the accepted wisdom is challenged. It is critical,
therefore, that such work continues since only then will new
opportunities for therapy and disease prevention emerge.
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